Oncology Corporate Profile
BeiGene is a global, clinical-stage, research-based company focused on targeted and immuno-oncology therapeutics. With a team of 175+ scientists and staff, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions that will have both a meaningful and lasting impact on cancer patients
Website: http://www.beigene.com/
Brand / Product | Class | Area of Study | Phase | Partnership |
---|---|---|---|---|
BGB-A317 | anti-PD-1 MAb inhibitor | Hepatocellular carcinoma (HCC) | I | |
BGB-283 | B-RAF inhibitor | Various cancer types | I |
View additional information on product candidates here »